Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Using technology spun out of UCSF, a new company hopes to develop oncology drugs that target effector mechanisms of protein synthesis, thereby affecting multiple oncogenes simultaneously. The San Diego-based biotech also hopes to license out its platform for non-cancer indications, bringing in non-dilutive money.

Advertisement

Related Content

Effector Selects Lead Cancer Compound, Looks Ahead To Combo Regimens
Start-Up Quarterly Statistics, Q2 2013
Biopharma Dealmaking Quarterly Statistics, Q2 2013
Financings Of The Fortnight: Biotech Enthusiasm Is Beginning To Bubble
Lumena Pharmaceuticals Takes $23M To Fight Rare Liver Disease
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Gilead Springs Further Into Oncology With Calistoga Acquisition

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel